Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bosentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 1.00 |
| ▸ | EDNRB known ✓ | P24530 | 12/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | DHPS | P49366 | 1/20 | 1.00 |
| ▸ | NR1H3 | Q13133 | 1/20 | 1.00 |
| ▸ | NR1I3 | Q14994 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bosentan SCHEMBL29485039 | 1.00 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL902870 | 1.00 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL3981779 | 1.00 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL615991 | 0.99 | EDNRA (0.98) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL977683 | 0.99 | EDNRA (0.98) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL2723442 | 0.99 | EDNRA (0.98) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL617167 | 0.99 | EDNRA (0.98) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL628837 | 0.99 | EDNRA (0.98) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL979668 | 0.99 | EDNRA (0.98) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL618415 | 0.99 | EDNRA (0.98) | EDNRAEDNRBABCC3ABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18379 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810091-B1 | COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION | ABRAXIS BIOSCIENCE LLC (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-3275429-B1 | TOPICAL OPHTHALMIC FORMULATION OF ENDOTHELIN RECEPTOR ANTAGONISTS | RETINSET S L (ES) | 2026-04-15 | — | — | EP | claimed |
| US-12577300-B2 | Neutralizing antibodies to human endothelin | Father Flanagan's Boys' Home Business (US) | 2026-03-17 | — | — | US | claimed |
| EP-4042999-B1 | DRUG ACCOMMODATING DEVICE OF SOLID ORAL FORMULATION, AND ORAL ADMINISTRATION AND DELIVERY APPARATUS COMPRISING SAME | SHANGHAI WD PHARMACEUTICAL CO LTD (CN) | 2026-03-04 | — | — | EP | claimed |
| EP-4696689-A1 | SALT FORM AND CRYSTAL FORM OF CHIRAL HETEROCYCLIC COMPOUND HAVING HEDGEHOG PATHWAY ANTAGONIST ACTIVITY | Suzhou Kintor Pharmaceuticals, Inc. (CN) | 2026-02-18 | — | — | EP | claimed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | claimed |
| EP-4691470-A1 | USE OF HETEROCYCLIC COMPOUND IN TREATMENT OF INTERSTITIAL PNEUMONIA | SUZHOU KINTOR PHARMACEUTICALS, INC (CN) | 2026-02-11 | — | — | EP | claimed |
| EP-4076461-B1 | LUMATEPERONE FOR USE IN SCHIZOPHRENIA TREATMENT | INTRA CELLULAR THERAPIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| CN-1182082-A | Preparation of pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 1998-05-20 | — | — | CN | claimed |
| EP-0841326-A1 | Process for the preparation of pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-05-13 | — | — | EP | claimed |
| EP-0838223-A1 | BRAIN EDEMA INHIBITOR | SHIONOGI & CO., LTD. (JP) | 1998-04-29 | — | — | EP | claimed |
| WO-1998016204-A1 | PROCESS FOR THE MANUFACTURE OF A PULVEROUS PREPARATION | F. HOFFMANN-LA ROCHE AG (CH) | 1998-04-23 | — | — | WO | claimed |
| US-5696116-A | TREATING DISORDERS ASSOCIATED WITH VASOCONSTRICTION | HOFFMANN-LA ROCHE INC. (US) | 1997-12-09 | — | — | US | claimed |
| US-5688499-A | Antagonism of endothelin actions | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1997-11-18 | — | — | US | claimed |
| WO-1997033608-A2 | ANTAGONISM OF ENDOTHELIN ACTIONS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1997-09-18 | — | — | WO | claimed |
| EP-0634175-A1 | Pharmaceutical combination, containing a renin-angiotensin-system inhibitor and an endothelin antagonist | F. HOFFMANN-LA ROCHE AG (CH) | 1995-01-18 | — | — | EP | claimed |
| US-5292740-A | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 1994-03-08 | — | — | US | claimed |
| EP-0526708-A1 | Sulfonamide, preparation and use thereof as medicine and intermediate | F. HOFFMANN-LA ROCHE AG (CH) | 1993-02-10 | — | — | EP | claimed |